Association between white matter hyperintensity and medial temporal atrophy at various stages of Alzheimer's disease

Kandiah, Nagaendran; Chander, Russell J.; Ng, Aloysius; Wen, Ming‐Ching; Cenina, Alvin Rae; Assam, Pryseley Nkouibert

doi:10.1111/ene.12546

Cited by 35 publications

(34 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the Alzheimer's Disease Diagnostic and Treatment Centers criteria, possible AD+CVD was common (31.3%), whereas VaD was less often observed (18.8%) according to the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherché et l'Enseignement en Neurosciences (NINDS‐AIREN) criteria . In a recent Asian study, 28.4% of patients with mild AD and 39.7% of those with moderate‐to‐severe AD had concomitant CVD in the form of white matter hyperintensity .…”

Section: Introductionmentioning

confidence: 99%

Alzheimer's disease with cerebrovascular disease: current status in the Asia–Pacific region

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Alzheimer's disease with cerebrovascular disease: current status in the Asia–Pacific region

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…In patients with AD, the larger volume of WMC might correlate with poor cognition, visuospatial memory and learning . WMC might also involve the transfer from non‐cognitive dysfunction to mild cognitive impairment and eventually to AD …”

Section: Introductionmentioning

confidence: 99%

Location of white matter changes and response to donepezil in patients with Alzheimer's disease: A retrospective and observational study

Kao

Chou

et al. 2017

Geriatrics Gerontology Int

View full text Add to dashboard Cite

Aim: The response to donepezil in patients with Alzheimer's disease varies, and it is important to identify the potential responder before therapy. Cerebral white matter changes (WMC) are frequently observed in older patients, and the effect of WMC on therapeutic response remains controversial. The present study aimed to investigate the relationships between the location of WMC, severe WMC and the response to donepezil. Results: There was no significant difference in demographic data between responder and non-responder groups. Patients in the responder group had significantly less involvement of WMC in the frontal area (P = 0.0213) and nearly a trend for less involvement of WMC in the basal ganglia (P = 0.1103). After adjustment for age, sex, education, polymorphism of apolipoprotein E, hypertension and diabetes, WMC in the frontal area (OR 0.446, P = 0.0139) and basal ganglia (OR 0.243, P = 0.0380) were significantly associated with a reduced therapeutic response.

show abstract

“…For example, larger studies at different disease stages across multiple clinics would help to determine if white matter hyperintensity (WMH) burden is indeed a stronger predictor of progressive brain atrophy in people with MCI and early AD than in later stages [28], [29]. Further studies are needed to determine how much co-occurring pathologies affect risk-benefit ratios of treatments that are typically used to reduce vascular risk, such as antithrombotic drugs.…”

Section: Resultsmentioning

confidence: 99%

METACOHORTS for the study of vascular disease and its contribution to cognitive decline and neurodegeneration: An initiative of the Joint Programme for Neurodegenerative Disease Research

Dichgans¹,

Wardlaw²,

Smith³

et al. 2016

Alzheimer's & Dementia

View full text Add to dashboard Cite

Dementia is a global problem and major target for health care providers. Although up to 45% of cases are primarily or partly due to cerebrovascular disease, little is known of these mechanisms or treatments because most dementia research still focuses on pure Alzheimer's disease. An improved understanding of the vascular contributions to neurodegeneration and dementia, particularly by small vessel disease, is hampered by imprecise data, including the incidence and prevalence of symptomatic and clinically “silent” cerebrovascular disease, long-term outcomes (cognitive, stroke, or functional), and risk factors. New large collaborative studies with long follow-up are expensive and time consuming, yet substantial data to advance the field are available. In an initiative funded by the Joint Programme for Neurodegenerative Disease Research, 55 international experts surveyed and assessed available data, starting with European cohorts, to promote data sharing to advance understanding of how vascular disease affects brain structure and function, optimize methods for cerebrovascular disease in neurodegeneration research, and focus future research on gaps in knowledge. Here, we summarize the results and recommendations from this initiative. We identified data from over 90 studies, including over 660,000 participants, many being additional to neurodegeneration data initiatives. The enthusiastic response means that cohorts from North America, Australasia, and the Asia Pacific Region are included, creating a truly global, collaborative, data sharing platform, linked to major national dementia initiatives. Furthermore, the revised World Health Organization International Classification of Diseases version 11 should facilitate recognition of vascular-related brain damage by creating one category for all cerebrovascular disease presentations and thus accelerate identification of targets for dementia prevention.

show abstract

Association between white matter hyperintensity and medial temporal atrophy at various stages of Alzheimer's disease

Cited by 35 publications

References 30 publications

Alzheimer's disease with cerebrovascular disease: current status in the Asia–Pacific region

Alzheimer's disease with cerebrovascular disease: current status in the Asia–Pacific region

Location of white matter changes and response to donepezil in patients with Alzheimer's disease: A retrospective and observational study

METACOHORTS for the study of vascular disease and its contribution to cognitive decline and neurodegeneration: An initiative of the Joint Programme for Neurodegenerative Disease Research

Contact Info

Product

Resources

About